Oxford, 16 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today announced that the Company’s Founder, Professor Carol Robinson, has been named the recipient of two prestigious awards; the 2019 Novozymes Prize and the Stein & Moore Award.
The 2019 Novozymes Prize was awarded to Carol for her scientific breakthroughs in the use of mass spectrometry for proteome analysis. Her methods have broad applicability in drug discoveryand have contributed to identifying both new protein drugs and new drug targets. The prize, given by the Novo Nordisk Foundation, aims to raise awareness of basic and applied biotechnology research and is awarded to recognise outstanding research or technology contributions that benefit the development of biotechnological science for innovative solutions.
Carol has also been named the 2019 recipient of the Stein & Moore Award, sponsored by The Protein Society. Named after Nobel laureates Dr William Stein and Dr Stanford Moore, the award is given to recognise eminent leaders in protein science who have made sustained high impact research contributions to the field. Her research on applications of mass spectrometry to the study of proteins and their interactions has resulted not only in new insights into protein structure and function, but has also established a new field, that of structural biology in the gas phase.
Professor Dame Carol Robinson, Founder & Scientific Advisor, OMass Therapeutics commented:
“I am extremely honoured to receive these prestigious awards. I have read the impressive list of previous recipients and am delighted to be joining the ranks of such eminent scientists.”
– Ends –
+44 (0)7818 430877
Notes for Editors:
About OMass Therapeutics
OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane proteins, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at: www.omass.com